WO2009103540A1 - Stabilisierung von dehydrogenasen mit stabilen coenzymen - Google Patents
Stabilisierung von dehydrogenasen mit stabilen coenzymen Download PDFInfo
- Publication number
- WO2009103540A1 WO2009103540A1 PCT/EP2009/001206 EP2009001206W WO2009103540A1 WO 2009103540 A1 WO2009103540 A1 WO 2009103540A1 EP 2009001206 W EP2009001206 W EP 2009001206W WO 2009103540 A1 WO2009103540 A1 WO 2009103540A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enzyme
- stabilized
- dehydrogenase
- nad
- coenzyme
- Prior art date
Links
- 239000005515 coenzyme Substances 0.000 title claims abstract description 86
- 108020005199 Dehydrogenases Proteins 0.000 title claims description 5
- 230000006641 stabilisation Effects 0.000 title description 12
- 238000011105 stabilization Methods 0.000 title description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 109
- 108090000790 Enzymes Proteins 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000012360 testing method Methods 0.000 claims abstract description 31
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 92
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims description 85
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 83
- 229950006238 nadide Drugs 0.000 claims description 79
- 238000003860 storage Methods 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 23
- 239000012491 analyte Substances 0.000 claims description 19
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 7
- 239000007791 liquid phase Substances 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229930024421 Adenine Natural products 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 claims description 2
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 claims description 2
- 108030000198 L-amino-acid dehydrogenases Proteins 0.000 claims description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 claims description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 claims description 2
- 229910052770 Uranium Inorganic materials 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 108010050201 2-hydroxybutyrate dehydrogenase Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 91
- DGPLSUKWXXSBCU-UHFFFAOYSA-N [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+](C2C(C(O)C(COP([O-])(=O)OP(O)(=O)OCC3C(C(O)C(O3)N3C4=NC=NC(N)=C4N=C3)O)C2)O)=C1 DGPLSUKWXXSBCU-UHFFFAOYSA-N 0.000 description 53
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- 239000008103 glucose Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- -1 acetyl NAD Chemical compound 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- KNTVBBGVOSDILJ-UHFFFAOYSA-N [n-(hydroxymethyl)-4-nitrosoanilino]methanol;hydrochloride Chemical compound Cl.OCN(CO)C1=CC=C(N=O)C=C1 KNTVBBGVOSDILJ-UHFFFAOYSA-N 0.000 description 7
- 238000005375 photometry Methods 0.000 description 7
- CTZNAAOWALUAJG-UHFFFAOYSA-N 4-(5-ethylphenazin-5-ium-1-yl)oxybutanoic acid;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1OCCCC(O)=O CTZNAAOWALUAJG-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000004008 5'-Nucleotidase Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010405 reoxidation reaction Methods 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ALNDFFUAQIVVPG-NGJCXOISSA-N (2r,3r,4r)-3,4,5-trihydroxy-2-methoxypentanal Chemical compound CO[C@@H](C=O)[C@H](O)[C@H](O)CO ALNDFFUAQIVVPG-NGJCXOISSA-N 0.000 description 1
- AAWUHVRMAVJMBD-IUYQGCFVSA-N (3s,4r)-3,4,5-trihydroxypentanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)CC(F)=O AAWUHVRMAVJMBD-IUYQGCFVSA-N 0.000 description 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KCALAFIVPCAXJI-UHFFFAOYSA-N 1,10-phenanthroline-5,6-dione Chemical class C1=CC=C2C(=O)C(=O)C3=CC=CN=C3C2=N1 KCALAFIVPCAXJI-UHFFFAOYSA-N 0.000 description 1
- JBLPWFLKCBTNBV-UHFFFAOYSA-N 1,7-phenanthroline-5,6-dione Chemical class C1=CC=C2C(=O)C(=O)C3=NC=CC=C3C2=N1 JBLPWFLKCBTNBV-UHFFFAOYSA-N 0.000 description 1
- JOUVLAZOIVGSAW-UHFFFAOYSA-M 1-methyl-1,10-phenanthrolin-1-ium-5,6-dione;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.O=C1C(=O)C2=CC=CN=C2C2=C1C=CC=[N+]2C JOUVLAZOIVGSAW-UHFFFAOYSA-M 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- KPVQNXLUPNWQHM-RBEMOOQDSA-N 3-acetylpyridine adenine dinucleotide Chemical compound CC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 KPVQNXLUPNWQHM-RBEMOOQDSA-N 0.000 description 1
- XSBUWCBZDKGGDQ-UHFFFAOYSA-N 7-methyl-6ah-1,7-phenanthrolin-1-ium-5,6-dione;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C1=C[NH+]=C2C3=CC=CN(C)C3C(=O)C(=O)C2=C1 XSBUWCBZDKGGDQ-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 102000000074 ADP-ribosyl Cyclase Human genes 0.000 description 1
- 108010080394 ADP-ribosyl Cyclase Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-altritol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229930191892 Formycin Natural products 0.000 description 1
- KBHMEHLJSZMEMI-UHFFFAOYSA-N Formycin A Natural products N1N=C2C(N)=NC=NC2=C1C1OC(CO)C(O)C1O KBHMEHLJSZMEMI-UHFFFAOYSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- ILAJVHULDFRDOI-UHFFFAOYSA-O NC(c1ccc[n+](CC(CC(COP(O)(O)=O)C2O)C2O)c1)=O Chemical compound NC(c1ccc[n+](CC(CC(COP(O)(O)=O)C2O)C2O)c1)=O ILAJVHULDFRDOI-UHFFFAOYSA-O 0.000 description 1
- KUFMXPZUZBPFCT-UHFFFAOYSA-N P(O)(OCOP(O)=O)=O Chemical compound P(O)(OCOP(O)=O)=O KUFMXPZUZBPFCT-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- FEYCFVFRMKWAOH-UHFFFAOYSA-N benzo[h]quinoline-2,3-dione Chemical class C1=CC=C2C3=NC(=O)C(=O)C=C3C=CC2=C1 FEYCFVFRMKWAOH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000840 electrochemical analysis Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- VEPYXRRTOARCQD-IGPDFVGCSA-N formycin Chemical compound N1=N[C]2C(N)=NC=NC2=C1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O VEPYXRRTOARCQD-IGPDFVGCSA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- KOOMFXGDLMRWSN-UHFFFAOYSA-N n-phenylnitrous amide Chemical class O=NNC1=CC=CC=C1 KOOMFXGDLMRWSN-UHFFFAOYSA-N 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- SCOAVUHOIJMIBW-UHFFFAOYSA-N phenanthrene-1,2-dione Chemical class C1=CC=C2C(C=CC(C3=O)=O)=C3C=CC2=C1 SCOAVUHOIJMIBW-UHFFFAOYSA-N 0.000 description 1
- 150000002988 phenazines Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01001—Alcohol dehydrogenase (1.1.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01006—Glycerol dehydrogenase (1.1.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01028—D-Lactate dehydrogenase (1.1.1.28)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01037—Malate dehydrogenase (1.1.1.37)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01047—Glucose 1-dehydrogenase (1.1.1.47)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
- C12Y104/01005—L-Amino-acid dehydrogenase (1.4.1.5)
Definitions
- the present invention relates to a method for stabilizing an enzyme by storing the enzyme in the presence of a stable coenzyme. Furthermore, the present invention relates to a stabilized with a stable coenzyme enzyme and its use in test elements for the detection of analytes.
- Biochemical measuring systems are important components of clinically relevant analytical methods.
- analytes e.g. Metabolites or substrates in the foreground, which are determined directly or indirectly by means of an enzyme.
- the analytes are hereby reacted with the aid of an enzyme-coenzyme complex and then quantified.
- the analyte to be determined is brought into contact with a suitable enzyme and a coenzyme, the enzyme usually being used in catalytic amounts.
- the coenzyme is altered by the enzymatic reaction, e.g. oxidized or reduced. This process can be detected electrochemically or photometrically directly or through a mediator.
- a calibration provides a direct correlation of the measured value with the concentration of the analyte to be determined.
- Coenzymes are organic molecules that are covalently or non-covalently bound to an enzyme and are altered by the reaction of the analyte.
- Prominent examples of coenzymes are nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which form NADH and NADPH by reduction.
- NAD nicotinamide adenine dinucleotide
- NADP nicotinamide adenine dinucleotide phosphate
- a known measure used to increase the stability of biochemical measuring systems is the use of stable enzymes, e.g. the use of enzymes from thermophilic organisms. Furthermore, it is possible to use enzymes by chemical modification, e.g. Crosslinking, or to stabilize by mutagenesis. In addition, enzyme stabilizers, e.g. Trehalose, polyvinylpyrrolidone and serum albumin, or the enzymes e.g. be included in polymer networks by photopolymerization.
- mediators with the lowest possible redox potential increases the specificity of tests and eliminates disturbances during the reaction.
- a lower limit for the redox potential of mediators is the redox potentials of the enzyme / coenzyme complexes. If these are undercut, the reaction with the mediators is slowed or even stopped.
- biochemical measuring systems without mediators, in which, for example, direct detection of coenzymes, for example of the coenzyme NADH, takes place.
- coenzymes such as NAD and NADP
- coenzymes are unstable.
- NAD and NADP are base-labile molecules whose degradation pathways are described in the literature (NJ Oppenheimer in The Pyridine Nucleotide Coenzyme Academic Press New York, London 1982, ed. J. Everese, B. Anderson, K. You, Chapter 3, pages 56- 65).
- the degradation of NAD or NADP produces ADP-ribose by cleaving the glycosyl bonds between the ribose and the pyridine moiety.
- NADH and NADPH are acid labile: for example, epimerization is a known degradation pathway.
- epimerization is a known degradation pathway.
- the instability of NAD / NADP and NADH / NADPH underlies the lability of glycosyl binding between the ribose and pyridine moieties.
- the hydrolysis of the coenzymes NAD or NADP is done solely by the ambient humidity. This instability can lead to inaccuracies in the measurement of analytes.
- NAD / NADP derivatives are used e.g. in B.M. Anderson in the Pyridine Nucleotide Coenzyme, Academic Press New York, London 1982, ed. J. Everese, B. Anderson, K. You, Chapter 4. However, most of these derivatives are not well accepted by enzymes.
- the only derivative heretofore used for diagnostic testing is 3-acetylpyridine-adenine dinucleotide (acetyl NAD), first described in 1956 (N.O. Kaplan, J. Biol. Chem. (1956), 221, 823). Also, this coenzyme shows a low acceptance of enzymes and a change in the redox potential.
- WO 01/94370 describes the use of further NAD derivatives with a modified pyridine group.
- modifications of the nicotinamide group generally have a direct influence on the catalytic reaction. In most cases this influence is negative.
- the ribose unit was altered to influence the stability of the glycosyl bond. This procedure does not directly interfere with the catalytic reaction of - A -
- Nicotinamide group there may be an indirect effect once the enzyme has strong and specific binding to the ribose moiety.
- Kaufmann et al. disclose a series of thioribose NAD derivatives.
- a connection between the modification of the nicotinamide ribose unit and the activity of the derivatives in enzymatic reactions has not yet been shown.
- carba NAD a derivative without glycosyl linkage
- the ribose is substituted herein by a carbacyclic sugar moiety.
- carbaNAD has been described as a substrate for dehydrogenases, its activity has not previously been demonstrated in biochemical detection in the clinic.
- WO 2007/012494 and US 11 / 460,366 disclose stable NAD / NADH or NADP / NADPH derivatives, enzyme complexes of these derivatives and their use in biochemical detection methods and reagent kits.
- the object underlying the present invention was to provide processes for the stabilization of enzymes, in particular for the long-term stabilization of enzymes.
- the enzyme stabilized by the method according to the invention is a coenzyme-dependent enzyme.
- Suitable enzymes are e.g. Dehydrogenases selected from a glucose dehydrogenase (EC 1.1.1.47), lactate dehydrogenase (EC1.1.1.27, 1.1.1.28), malate dehydrogenase (EC1.1.1.37), glycerol dehydrogenase (EC1.1.1.6), alcohol Dehydrogenase (EC1.1.1.1), alpha-hydroxybutyrate
- Dehydrogenase sorbitol dehydrogenase or amino acid dehydrogenase, e.g. B. L-amino acid dehydrogenase (E.C.1.4.1.5).
- Other suitable enzymes are oxidases, such as glucose oxidase (E.C.1.1.3.4) or cholesterol oxidase (E.C.1.1.3.6) or aminotransferases, such as. Aspartate or alanine aminotransferase, 5'-nucleotidase or creatine kinase.
- the enzyme is glucose dehydrogenase.
- mutated glucose dehydrogenase In the context of the method according to the invention, the use of a mutated glucose dehydrogenase has proven to be particularly preferred.
- mutant as used in the present application is used, denotes a genetically modified variant of a native enzyme which has the same number of amino acids compared to the wild-type enzyme modified amino acid sequence, that is different in at least one amino acid from the wild-type enzyme.
- the introduction of the mutation (s) may be site-specific or non-site specific, preferably site-specific using recombinant methods known in the art, resulting in at least one amino acid substitution within the amino acid sequence of the native enzyme according to the particular requirements and conditions.
- the mutant particularly preferably has an increased thermal or hydrolytic stability compared to the wild-type enzyme.
- the mutated glucose dehydrogenase may in principle contain the amino acid (s) modified from the corresponding wild-type glucose dehydrogenase at any position of its amino acid sequence.
- the mutant glucose dehydrogenase comprises a mutation at least one of positions 96, 170 and 252 of the amino acid sequence of wild-type glucose dehydrogenase, with mutants having mutations at position 96 and position 170 or mutations at position 170 and position 252 being particularly preferred , It has proved to be advantageous if the mutated glucose dehydrogenase contains no further mutations in addition to these mutations.
- the mutation at positions 96, 170 and 252 may in principle comprise any amino acid substitution which leads to a stabilization, for example an increase in the thermal or hydrolytic stability, of the wild-type enzyme.
- the mutation at position 96 comprises an amino acid substitution of glutamic acid for glycine, while with respect to position 170, an amino acid substitution of glutamic acid for arginine or lysine, in particular an amino acid substitution of glutamic acid for lysine, is preferred.
- the mutation at position 252 it preferably comprises an amino acid substitution of lysine for leucine.
- the mutant glucose dehydrogenase can be obtained by mutation of a wild-type glucose dehydrogenase derived from any biological source, the term "biological source” for the purposes of this invention including prokaryotes, such as bacteria, and eukaryotes, such as mammals and others
- the wild-type glucose dehydrogenase is derived from a bacterium, more preferably a glucose dehydrogenase from Bacillus megaterium, Bacillus subtilis or Bacillus thuringiensis, in particular from Bacillus subtilis.
- the mutated glucose dehydrogenase is a glucose dehydrogenase obtained by mutation of wild-type glucose dehydrogenase from Bacillus subtilis which has the sequence shown in SEQ ID NO: 1 (GlucDH_E96G_E170K) or SEQ ID NO: 1 ID NO: 2 (GlucDH_E170K_K252L) has the amino acid sequence shown.
- the stable coenzyme is a coenzyme chemically altered from the native coenzyme, which has higher stability (e.g., hydrolytic stability) compared to the native coenzyme.
- the stable coenzyme is stable to hydrolysis under test conditions.
- the stable coenzyme can be a decreased
- stable coenzymes are stable derivatives of nicotinamide adenine dinucleotide (NAD / NADH) or nicotinamide adenine dinucleotide phosphate (NADP / NADPH), or truncated NAD derivatives, eg without AMP moiety or with non-nucleosidic residues, eg hydrophobic residues.
- a stable coenzyme in the context of the present invention is the compound of the formula (I)
- stable derivatives of NAD / NADH or NADP / NADPH are described in the aforementioned references, the disclosure of which is incorporated herein by reference.
- Particularly preferred stabilized coenzymes are described in WO 2007/012494 and US Pat. No. 11 / 460,366, the disclosure of which is hereby expressly incorporated by reference.
- the stable coenzyme is more preferably selected from compounds of general formula (II):
- A adenine or an analogue thereof
- T each independently O
- S each independently OH
- SH each independently OH
- BH 3 " , BCNH 2 "
- V each independently OH or a phosphate group, or two
- X 1 , X 2 each independently O, CH 2 , CHCH 3 , C (CH 3 J 2 , NH, NCH 3 ,
- Y NH 1 S 1 O 1 CH 2
- Z a linear or cyclic organic radical, with the proviso that Z and the pyridine radical are not linked by a glycosidic compound, or
- Z is particularly preferably a saturated or unsaturated carbocyclic or heterocyclic five-membered ring, in particular a compound of the general formula (III)
- R 5 'and R 5 may be a single or double bond
- the compounds of the invention contain adenine or adenine analogs such as C 8 and N 6 substituted adenine, deaza variants such as 7-deaza, azavaries such as 8-aza, or combinations such as 7-deaza or 8-aza or carbocyclic analogs, such as formycin, where the 7-deaza variants in the 7-position may be substituted by halogen, C 1 -C 6 -alkynyl, -alkenyl or -alkyl.
- the compounds adenosine analogues which take ribose, for example, 2-methoxy-deoxyribose, 2 1 - Fluoro-deoxyribose, hexitol, altritol or polycyclic analogs containing as bicyclo-, LNA and tricyclo sugar.
- ribose for example, 2-methoxy-deoxyribose, 2 1 - Fluoro-deoxyribose, hexitol, altritol or polycyclic analogs containing as bicyclo-, LNA and tricyclo sugar.
- W is preferably CONH 2 or COCH 3 .
- R 5 is preferably CH 2 . Furthermore, it is preferred that R 51 is selected from CH 2 , CHOH and NH. In a particularly preferred embodiment, R 5 'and R 5 "are each CHOH. In yet another preferred embodiment, R 51 is NH and R 5 " is CH 2 . Specific examples of preferred stabilized coenzymes are shown in Figures 1A and B.
- the stable coenzyme to carbaNAD In the most preferred embodiment, the stable coenzyme to carbaNAD.
- the inventive method is in particular for
- enzymes suitable Long-term stabilization of enzymes suitable. This means that the enzyme stabilized with a stable coenzyme, e.g. as a dry substance, for example over a period of at least 2 weeks, preferably of at least 4 weeks and more preferably of at least
- the method according to the invention comprises a storage of the stabilized with a stable coenzyme enzyme at elevated temperatures, for example at a temperature of at least 20 0 C, preferably of at least 25 0 C and more preferably of at least 30 0 C.
- the enzyme activity preferably decreases by less than 50%, more preferably less than 30%, and most preferably less than 20% of their initial value.
- the stabilization according to the invention makes it possible to store the stabilized enzyme with a stable coenzyme without drying reagent for a long time, as indicated above, and / or at high temperatures, as indicated above. Furthermore, the stabilized enzyme may also be maintained at a high relative humidity, e.g. a relative humidity of at least 50%, wherein the enzyme activity preferably decreases by less than 50%, more preferably less than 30% and most preferably less than 20% of the initial value.
- a high relative humidity e.g. a relative humidity of at least 50%
- the storage of the stabilized with a stable coenzyme enzyme can be done on the one hand as dry matter and on the other hand in liquid phase.
- the storage of the stabilized enzyme preferably takes place on or in a test element which is suitable for the determination of an analyte.
- That with a stable coenzyme stabilized enzyme is preferably part of a detection reagent, which may optionally contain other ingredients such as salts, buffers, etc.
- the detection reagent is free from a mediator.
- the stabilized with a stable coenzyme enzyme can be used for the detection of analytes, such as parameters in body fluids such as blood, serum, plasma or urine or in wastewater samples or food.
- any biological or chemical substances which can be detected by a redox reaction e.g. Substances that are substrates of a coenzyme-dependent enzyme or coenzyme-dependent enzymes themselves.
- Preferred examples of analytes are glucose, lactic acid, malic acid, glycerol, alcohol, cholesterol, triglycerides, ascorbic acid, cysteine, glutathione, peptides, urea , Ammonium, salicylate, pyruvate, 5'-nucleotidase, creatine kinase (CK), lactate dehydrogenase (LDH), carbon dioxide, etc.
- the analyte is glucose. 0
- Another object of the present invention is the use of a compound of the invention or a stabilized with a stable coenzyme enzyme for the detection of an analyte in a sample by an enzymatic reaction.
- a compound of the invention or a stabilized with a stable coenzyme enzyme for the detection of an analyte in a sample by an enzymatic reaction.
- Particularly preferred here is the detection of glucose with the aid of glucose dehydrogenase (GlucDH).
- the change of the stable coenzyme by reaction with the analyte can basically be detected in any way.
- all methods known from the prior art for detecting enzymatic reactions can be used.
- the change in the coenzyme is detected by optical methods.
- Optical detection methods include, for example, the Measurement of absorption, fluorescence, circular dichroism (CD), optical rotation dispersion (ORD), refractometry etc.
- An optical detection method which is preferably used in the context of the present application, is photometry.
- photometry For the photometric measurement of a change in the coenzyme due
- Nitrosoanilines such as [(4-nitrosophenyl) imino] dimethanol hydrochloride, quinones such as phenanthrenequinones, phenanthroline quinones or benzo [h] quinoline quinones, phenazines such as 1- (3-carboxypropoxy) -5-ethylphenazinium trifluoromethanesulfonate, or / and diaphorase (EC 1.6.99.2).
- Preferred examples of phenanthroline quinones include 1, 10-phenanthroline-5,6-quinones, 1, 7-phenanthroline-5,6-quinones, 4,7-quinones,
- Phenanthroline-5,6-quinones and their N-alkylated or N, N'-dialkylated salts wherein in the case of N-alkylated or N, N'-dialkylated salts halides, trifluoromethanesulfonate or other solubility enhancing anions are preferred as the counterion.
- any substance can be used which is reducible and upon reduction undergoes a detectable change in its optical properties, such as color, fluorescence, remission, transmission, polarization and / or refractive index.
- the determination of the presence or / and the amount of the analyte in the sample can be done with the naked eye and / or by means of a detection device using a photometric method which appears to be suitable for the person skilled in the art.
- heteropolyacids, and especially 2,18-phosphomolybdic acid are used as optical indicators which are reduced to the corresponding heteropolyblue.
- the change in the coenzyme is detected by measuring the fluorescence.
- the fluorescence measurement is highly sensitive and enables the detection even of low concentrations of the analyte in miniaturized systems.
- the change in coenzyme can also be detected electrochemically using a suitable test element, such as an electrochemical test strip.
- a suitable test element such as an electrochemical test strip.
- suitable mediators which can be converted by the reduced coenzyme by transferring electrons into a reduced form.
- the analyte is determined by measuring the current required for reoxidation of the reduced mediator, which correlates with the concentration of the analyte in the sample.
- mediators that can be used for electrochemical measurements include in particular the aforementioned mediators used for photometric measurements.
- a liquid test may be used, the reagent being e.g. in the form of a solution or suspension in an aqueous or non-aqueous liquid or as a powder or lyophilisate.
- a dry test may also be used wherein the reagent is applied to a carrier, a test strip.
- the carrier may comprise a test strip comprising an absorbent and / or swellable material which is wetted by the sample liquid to be examined.
- a particularly preferred assay format involves the use of the enzyme glucose dehydrogenase with a stable NAD derivative to detect glucose, wherein a derivative of the reduced coenzyme NADH is formed.
- the detection of NADH is carried out by optical methods, eg by photometric or fluorometric determination after UV excitation.
- a particularly preferred test system is described in US 2005/0214891, which is incorporated herein by reference.
- a still further object of the present invention is a stabilized with a stable coenzyme enzyme, wherein the stabilized enzyme at a storage of preferably at least 2 weeks, more preferably at least 4 weeks and most preferably at least 8 weeks at a temperature of preferably at least 20 0 C. , more preferably at least 25 ° C., and most preferably at least 30 ° C., optionally at high humidity and without dry reagent, a decrease in enzymatic activity of less than 50%, preferably less than 30% and most preferably less than 20% from baseline having.
- Yet another object of the invention is a detection reagent for the determination of an analyte which contains a stabilized with a stable coenzyme enzyme, as indicated above.
- the invention relates to a test element which contains a stabilized enzyme or a detection reagent according to the invention.
- the detection reagent or the test element may be suitable by performing dry or liquid tests.
- the test element is a test strip for the fluorometric or photometric detection of an analyte.
- Such a test strip contains the stable coenzyme stabilized enzyme immobilized on an absorbent or / and swellable material, such as cellulose, plastics, etc.
- Figure 1A Representation of the stable coenzyme carba-NAD (cNAD).
- Figure 1 B Representation of the stable coenzyme pyrrolidinyl-NAD.
- Figure 2 Representation of the results of the enzyme kinetics of glucose dehydrogenase in the presence of NAD or of glucose dehydrogenase in the presence of cNAD before and after storage.
- Figure 2A Kinetics of GlucDH in the presence of NAD after 1 day.
- 2B Kinetics of GlucDH in the presence of cNAD after 1 day.
- 2C Kinetics of GlucDH in the presence of NAD after 5 weeks of storage at 32 0 C and 85% relative humidity.
- 2D Kinetics of GlucDH in the presence of cNAD after 5 weeks of storage at 32 0 C and 85% relative humidity.
- Figure 3 Comparison of Blank values of glucose-dehydrogenase in the presence of NAD or of GlucDH in the presence of cNAD over a period of up to 5 weeks at 32 C C and 85% humidity.
- Figure 4 Representation of various functional curves of glucose dehydrogenase after storage of glucose dehydrogenase in the presence of NAD at 32 0 C and 85% humidity. The storage duration varied between 1 day and 5 weeks.
- Figure 5 Representation of various functional curves of glucose dehydrogenase after storage of glucose dehydrogenase in the presence of cNAD at 32 0 C and 85% humidity. The storage period varied between 1 day and 5 weeks (FIG. 5A) or between 1 day and 24 weeks (FIG. 5B).
- Figure 6 Representation of the residual content of NAD or cNAD after storage of glucose dehydrogenase in the presence of NAD or cNAD for 24 weeks at 32 0 C and 85% humidity.
- FIG. 7 Representation of GlucDH activity after storage of glucose Dehydrogenase in the presence of NAD or cNAD over 5 weeks ( Figure 7A) and 24 weeks ( Figure 7B) at 32 0 C and 85% humidity.
- FIG. 8 Representation of GlucDH activity after storage of glucose dehydrogenase (GlucDH wt), the double mutant GlucDH_E96G_E170K (GlucDH Mut1) and the double mutant GlucDH_E170K_K252L (GlucDH Mut2) over a period of 25 weeks in the presence of NAD or cNAD at 32 0 C and 83% relative humidity.
- GlucDH wt glucose dehydrogenase
- GlucDH Mut1 double mutant GlucDH_E96G_E170K
- GlucDH Mut2 double mutant GlucDH_E170K_K252L
- FIG. 9 Gel electrophoretic analysis of glucose dehydrogenase after storage in the presence of NAD or cNAD. Test conditions: MW, 10-220 kDa markers; 1: GlucDH / NAD, 5 weeks at 6 0 C; 2: GlucDH / NAD, 5 weeks at 32 ° C / 85% relative humidity; 3: GlucDH / cNAD, 5 weeks at 6 0 C; 4: GlucDH / cNAD, 5 weeks at 32 ° C / 85% relative humidity.
- Figure 10 Gel electrophoretic analysis of glucose dehydrogenase after storage at 50 0 C in the presence of NAD or cNAD. Test conditions: MW, 10-220 kDa markers; 1: GlucDH 8.5 mg / ml, NAD, 0 hours; 2: GlucDH 8.5 mg / ml, NAD, 22 hours; 3: GlucDH 8.5 mg / ml, NAD, 96 hours; 4: GlucDH 8.5 mg / ml, NAD, 118 hours; 5: GlucDH 8.5 mg / ml, NAD 1 140 hours; 6: GlucDH 8.5 mg / ml, NAD, 188 hours; 7: GlucDH 8.5 mg / ml, NAD, 476 hours; 8: GlucDH 8.5 mg / ml, cNAD, 0 hours; 9: GlucDH 8.5 mg / ml, cNAD, 188 hours; 10: GlucDH 8.5 mg / ml,
- Figure 11 Representation of the stability of glucose dehydrogenase in the presence of NAD or cNAD in liquid phase at 50 0 C over a period of 4 days ( Figure 11A) and 14 days ( Figure 11B).
- Test conditions GlucDH 10 mg / ml; NAD or cNAD 12 mg / ml; Buffer: 0.1 M Tris, 1.2 M NaCl, pH 8.5; Temperature 50 ° C.
- FIG. 12 Gel electrophoretic analysis of alcohol dehydrogenase Yeast after storage in the presence of NAD or cNAD. Test conditions: MW, 10-220 kDa markers; 1: ADH 1 65 hours at 6 0 C; 2: ADH / cNAD, 65 hours at 6 0 C; 3: ADH / NAD, 65 hours at 60 ° C; 4: ADH, 65 hours at 35 ° C .; 5: ADH / cNAD, 65 hours at 35 0 C; 6: ADH / NAD, 65 hours at 35 ° C.
- Figure 13 Gel electrophoretic analysis of alcohol dehydrogenase from yeast after storage at 35 0 C in the presence of NAD or cNAD.
- Test conditions MW, 10-220 kDa markers; 1: ADH / NAD, 0 days; 2: ADH / NAD, 1 day; 3: ADH / NAD, 2 days; 4: ADH / NAD, 3 days; 5: ADH / NAD, 5 days; 6: ADH / cNAD, 0 days; 7: ADH / cNAD, 1 day; 8: ADH / cNAD, 2 days; 9: ADH / cNAD, 3 days; 10: ADH / cNAD, 6 days.
- Figure 14 Representation of the stability of alcohol dehydrogenase from yeast in the presence of NAD or cNAD in liquid phase at 35 0 C over a period of 65 hours.
- Test conditions ADH 5 mg / ml; NAD or cNAD 50 mg / ml; Buffer: 75 mM Na 4 P 2 O 7 , glycine, pH 9.0; Temperature 35 ° C.
- FIG. 15 Illustration of various functional curves of glucose dehydrogenase after 11 weeks of storage in the presence of NAD and different mediators at room temperature.
- FIG. 16 Preparation of the results of the enzyme kinetics of glucose dehydrogenase in the presence of NAD and 1- (3-carboxypropoxy) -5-ethylphenazinium trifluoromethanesulfonate at various glucose concentrations.
- FIG. 17 Schematic representation of the glucose detection with GlucDH as enzyme and diaphorase as mediator.
- Figure 18 Representation of the functional curves of glucose-dye oxidoreductase (GlucDOR) in the presence of pyrroloquinoline quinone (PQQ) and [(4-nitrosophenyl) imino] dimethanol hydrochloride as a mediator or of Glucose dehydrogenase in the presence of NAD and diaphorase / [(4-nitrosophenyl) imino] dimethanol hydrochloride as a mediator.
- PQQ pyrroloquinoline quinone
- NAD and diaphorase / [(4-nitrosophenyl) imino] dimethanol hydrochloride as a mediator.
- FIG. 19 Representation of the results of the enzyme kinetics of glucose dehydrogenase in the presence of NAD and diaphorase at various glucose concentrations.
- FIG. 20 Representation of the current measured as a function of the glucose concentration during the electrochemical determination of glucose using glucose dehydrogenase in the presence of NAD or cNAD. Test conditions: 25 mM NAD or cNAD; 2.5 seconds delay; 5 seconds measurement time.
- Figure 21 Representation of the amino acid sequences of the glucose dehydrogenase double mutant GlucDH_E96G_E170K and
- Glucose-specific GlucDH was added to carba-NAD (Fig. 1A) or NAD. These formulations were each applied to Pokalon (Lonza) and stored after drying under warm and humid conditions (32 0 C, 85% relative humidity). Subsequently, the reaction kinetics and the function curve were determined at regular intervals. At the same time, a cNAD / NAD analysis and a determination of the residual activity of the enzyme was performed at the respective measurement dates.
- the relationship between the structure of the coenzyme and its stability over a predetermined period of time is derived from Figure 6. Accordingly, the residual content of cNAD is in a glucose-detecting reagent after 24 weeks of storage (at 32 0 C and 85% relative humidity) for about 80% of the Initial level, while the content of NAD in an NAD-stabilized glucose detection reagent already after 5 weeks to about 35% of the initial value decreases and after extrapolation after about 17 weeks to zero.
- the residual activity of GlucDH can be further increased.
- the residual activity of a mutant GlucDH_E96G_E170K with amino acid substitutions glutamic acid is ⁇ glycine at position 96 and glutamic acid ⁇ lysine at position 170 (GlucDH Mut1) of the wild type enzyme approximately 70% while the residual activity of a mutant GlucDH_E170K_K252L with
- Presence of cNAD stored enzyme against a band detected at the beginning of the experiment shows only a slight change.
- glucose dehydrogenase For the determination of glucose, various test systems, each comprising glucose dehydrogenase, NAD 1 a mediator and optionally an optical indicator were measured photometrically or electrochemically.
- FIG. 18 shows for the system glucose dehydrogenase, NAD, diaphorase, [(4-nitrosophenyl) imino] dimethanol hydrochloride and 2.18-
- Phosphomolybdic acid (system 1) a concentration-dependent decrease in remission.
- system glucose-dye oxidoreductase, pyrroloquinoline quinone, [(4-nitrosophenyl) imino] dimethanol hydrochloride and 2,18-phosphomolybdic acid (System 2), which likewise causes a concentration-dependent decrease in remission, due to the low specificity of glucose DYE oxidoreductase but has disadvantages.
- the kinetics of the conversion of glucose by means of the system 1 at glucose concentrations in the range of 0 to 800 mg / dl is shown in FIG.
- an electrochemical measurement can also be used for the purpose of determining the analyte.
- a test element which, in addition to glucose dehydrogenase, contained NAD as coenzyme and 1- (3-carboxypropoxy) -5-ethylphenazinium trifluoromethanesulfonate as mediator, as well as for a corresponding system comprising the stabilized coenzyme cNAD instead of NAD , a linear dependence of the current required for reoxidation of the reduced mediator on the glucose concentration ( Figure 20).
- the analyte determination using the system dehydrogenase / stable coenzyme can also be carried out by means of electrochemical detection and evaluation with a different wavelength, which is independent of the coenzyme.
- the stable enzyme / coenzyme pair the total formulation should also be further stabilized.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ587397A NZ587397A (en) | 2008-02-19 | 2009-02-19 | Stabilization of dehydrogenases using stable chemically modified coenzymes |
KR1020127027270A KR20120134142A (ko) | 2008-02-19 | 2009-02-19 | 안정한 조효소를 사용하는 탈수소효소의 안정화 |
CA2721718A CA2721718C (en) | 2008-02-19 | 2009-02-19 | Stabilization of dehydrogenases with stable coenzymes |
JP2010547110A JP5758128B2 (ja) | 2008-02-19 | 2009-02-19 | 安定な補酵素による脱水素酵素の安定化 |
CN200980105640.6A CN101945999B (zh) | 2008-02-19 | 2009-02-19 | 使用稳定辅酶的脱氢酶稳定作用 |
EP09712033.1A EP2245152B1 (de) | 2008-02-19 | 2009-02-19 | Stabilisierung von dehydrogenasen mit stabilen coenzymen |
MX2010008920A MX2010008920A (es) | 2008-02-19 | 2009-02-19 | Estabilizacion de deshidrogenasas utilizando coenzimas estables. |
RU2010138610/10A RU2499834C2 (ru) | 2008-02-19 | 2009-02-19 | Стабилизация дегидрогеназ стабильными коферментами |
KR1020107020894A KR101381004B1 (ko) | 2008-02-19 | 2009-02-19 | 안정한 조효소를 사용하는 탈수소효소의 안정화 |
BRPI0907839-8A BRPI0907839A2 (pt) | 2008-02-19 | 2009-02-19 | Estabilização de desidrogenases com coenzimas estáveis |
AU2009216908A AU2009216908B9 (en) | 2008-02-19 | 2009-02-19 | Stabilization of dehydrogenases using stable coenzymes |
KR1020137013118A KR20130081300A (ko) | 2008-02-19 | 2009-02-19 | 안정한 조효소를 사용하는 탈수소효소의 안정화 |
CA2750474A CA2750474C (en) | 2009-02-19 | 2010-02-12 | Fast reaction kinetics of enzymes having low activity in dry chemistry layers |
CN2010800085457A CN102325896A (zh) | 2008-02-19 | 2010-02-12 | 干化学层中具有低活性的酶的快速反应动力学 |
KR1020117019082A KR101604624B1 (ko) | 2009-02-19 | 2010-02-12 | 건식 화학 층에서 낮은 활성을 갖는 효소의 고속 반응 속도 |
JP2011550531A JP6113405B2 (ja) | 2008-02-19 | 2010-02-12 | 乾式試薬層において低い活性を有する、速い反応速度の酵素 |
MX2011008669A MX2011008669A (es) | 2009-02-19 | 2010-02-12 | Cineticos de reaccion rapida de enzimas que tienen baja actividad en capas quimicas secas. |
KR1020137029083A KR20130127555A (ko) | 2009-02-19 | 2010-02-12 | 건식 화학 층에서 낮은 활성을 갖는 효소의 고속 반응 속도 |
PCT/EP2010/051801 WO2010094632A1 (de) | 2009-02-19 | 2010-02-12 | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten |
EP10704923.1A EP2398909B1 (de) | 2009-02-19 | 2010-02-12 | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten |
US12/859,654 US9896666B2 (en) | 2008-02-19 | 2010-08-19 | Stabilization of dehydrogenases with stable coenzymes |
ZA2010/06638A ZA201006638B (en) | 2008-02-19 | 2010-09-16 | Stabilization of dehydrogenases using stable coezymes |
US13/210,564 US9359634B2 (en) | 2009-02-19 | 2011-08-16 | Fast reaction kinetics of enzymes having low activity in dry chemistry layers |
US15/868,055 US11220674B2 (en) | 2008-02-19 | 2018-01-11 | Stabilization of dehydrogenases with stable coenzymes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08003054A EP2093284A1 (de) | 2008-02-19 | 2008-02-19 | Stabilisierung von Dehydrogenasen mit stabilen Coenzymen |
EP08003054.7 | 2008-02-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/859,654 Continuation US9896666B2 (en) | 2008-02-19 | 2010-08-19 | Stabilization of dehydrogenases with stable coenzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009103540A1 true WO2009103540A1 (de) | 2009-08-27 |
Family
ID=39768713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/001206 WO2009103540A1 (de) | 2008-02-19 | 2009-02-19 | Stabilisierung von dehydrogenasen mit stabilen coenzymen |
Country Status (15)
Country | Link |
---|---|
US (2) | US9896666B2 (de) |
EP (2) | EP2093284A1 (de) |
JP (2) | JP5758128B2 (de) |
KR (3) | KR20120134142A (de) |
CN (3) | CN104450659A (de) |
AR (1) | AR070436A1 (de) |
AU (1) | AU2009216908B9 (de) |
BR (1) | BRPI0907839A2 (de) |
CA (1) | CA2721718C (de) |
HK (1) | HK1208703A1 (de) |
MX (1) | MX2010008920A (de) |
RU (1) | RU2499834C2 (de) |
TW (1) | TWI482860B (de) |
WO (1) | WO2009103540A1 (de) |
ZA (1) | ZA201006638B (de) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010094632A1 (de) * | 2009-02-19 | 2010-08-26 | F. Hoffmann-La Roche Ag | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten |
CN102325896A (zh) * | 2008-02-19 | 2012-01-18 | 霍夫曼-拉罗奇有限公司 | 干化学层中具有低活性的酶的快速反应动力学 |
US20130052674A1 (en) * | 2009-12-16 | 2013-02-28 | Carina Horn | Detecting the decomposition of enzymes in a test element by means of controlled release of a protected analyte |
WO2013189880A1 (en) | 2012-06-22 | 2013-12-27 | Roche Diagnostics Gmbh | Method and device for detecting an analyte in a body fluid |
WO2014096174A1 (en) | 2012-12-20 | 2014-06-26 | Roche Diagnostics Gmbh | Method for evaluating medical measurement curves |
EP2781919A1 (de) | 2013-03-19 | 2014-09-24 | Roche Diagniostics GmbH | Verfahren/Vorrichtung zur Erzeugung eines korrigierten Werts einer Analytenkonzentration in einer Körperflüssigkeitsprobe |
WO2014180939A1 (en) | 2013-05-08 | 2014-11-13 | Roche Diagnostics Gmbh | Stabilization of enzymes by nicotinic acid |
EP2927319A1 (de) | 2014-03-31 | 2015-10-07 | Roche Diagnostics GmbH | Hochlastenzymimmobilisierung mittels Quervernetzung |
WO2016026959A1 (en) | 2014-08-22 | 2016-02-25 | Roche Diagnostics Gmbh | Redoxindicators |
US9359634B2 (en) | 2009-02-19 | 2016-06-07 | Roche Diabetes Care, Inc. | Fast reaction kinetics of enzymes having low activity in dry chemistry layers |
WO2018067235A1 (en) | 2016-10-05 | 2018-04-12 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
US9988358B2 (en) | 2014-04-14 | 2018-06-05 | Roche Diagnostics Operations, Inc. | Phenazinium mediators |
EP3339431A1 (de) | 2016-12-22 | 2018-06-27 | Roche Diabetes Care GmbH | Glucosedehydrogenasevarianten mit verbesserten eigenschaften |
US10168321B2 (en) | 2013-11-27 | 2019-01-01 | Roche Diabetes Care, Inc. | Composition comprising up-converting phosphors for detecting an analyte |
WO2019166394A1 (en) | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | Biocompatibility coating for continuous analyte measurement |
US11060978B2 (en) | 2012-12-20 | 2021-07-13 | Roche Diabetes Care, Inc. | Methods of determining an analyte concentration in a body fluid sample having disturbance variables, as well as computer programs and devices therefor |
US11105800B2 (en) | 2013-10-29 | 2021-08-31 | Roche Diabetes Care, Inc. | Nano-enzyme containers for test elements |
US12024735B2 (en) | 2021-12-10 | 2024-07-02 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4786451B2 (ja) * | 2005-07-28 | 2011-10-05 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | Nad/nadhの安定化 |
EP2226007A1 (de) | 2009-02-19 | 2010-09-08 | Roche Diagnostics GmbH | Testelementmagazin mit abgedeckten Testfeldern |
WO2010094427A2 (de) | 2009-02-19 | 2010-08-26 | Roche Diagnostics Gmbh | Platzsparende magazinierung analytischer hilfsmittel |
EP2226008A1 (de) | 2009-02-19 | 2010-09-08 | Roche Diagnostics GmbH | Verfahren zur Herstellung eines analytischen Magazins |
EP2292751A1 (de) * | 2009-08-20 | 2011-03-09 | Roche Diagnostics GmbH | Stabilisierung von Enzymen mit stabilen Coenzymen |
EP2636750A1 (de) * | 2012-03-06 | 2013-09-11 | Roche Diagniostics GmbH | Kompatibles gelöstes Ectoin sowie Derivate davon zur Enzymstabilisierung |
US8921061B2 (en) * | 2012-11-02 | 2014-12-30 | Roche Diagnostics Operations, Inc. | Reagent materials and associated test elements |
US8920628B2 (en) | 2012-11-02 | 2014-12-30 | Roche Diagnostics Operations, Inc. | Systems and methods for multiple analyte analysis |
WO2014195363A1 (en) * | 2013-06-04 | 2014-12-11 | Roche Diagnostics Gmbh | Novel compounds useful for fret and methods related thereto |
CN107779459B (zh) * | 2016-08-31 | 2021-06-08 | 安琪酵母股份有限公司 | 葡萄糖脱氢酶dna分子、载体和菌株及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033936A1 (en) * | 1997-02-04 | 1998-08-06 | Specialty Assays, Inc. | The use of nadph and nadh analogs in the measurement of enzyme activities and metabolites |
WO2001049247A2 (en) * | 1999-12-30 | 2001-07-12 | Specialty Assays, Inc. | Assays for analytes and enzymes practiced in the presence of nad and nadp analogues, and related assay kits |
US20070026476A1 (en) * | 2005-07-28 | 2007-02-01 | Dieter Heindl | Compounds, methods, complexes, apparatuses and uses relating to stabile forms of nad/nadh |
WO2007012494A1 (de) * | 2005-07-28 | 2007-02-01 | F.Hoffmann-La Roche Ag | Stabile nad/nadh-derivate |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1043568A1 (ru) * | 1981-06-11 | 1983-09-23 | Московский Ордена Ленина,Ордена Октябрьской Революции И Ордена Трудового Красного Знамени Государственный Университет Им.М.В.Ломоносова | Способ определени активности дегидрогеназ крови |
DE19543493A1 (de) * | 1995-11-22 | 1997-05-28 | Boehringer Mannheim Gmbh | Stabilisierte Coenzym-Lösungen und deren Verwendung zur Bestimmung von Dehydrogenasen bzw. deren Substrate im alkalischen Milieu |
WO2001094370A1 (fr) | 2000-06-07 | 2001-12-13 | Wako Pure Chemical Industries, Ltd. | Derives de coenzymes et enzymes appropries |
ATE364086T1 (de) * | 2000-10-31 | 2007-06-15 | Koji Sode | Neue glucosedehydrogenase und verfahren zur herstellung der dehydrogenase |
JP2003310274A (ja) * | 2002-04-30 | 2003-11-05 | Amano Enzyme Inc | グルコース脱水素酵素およびそれをコードする遺伝子 |
CN1653189B (zh) | 2002-05-16 | 2010-12-15 | 霍夫曼-拉罗奇有限公司 | 制备聚合物涂层的方法 |
US7816111B2 (en) * | 2003-08-11 | 2010-10-19 | Codexis, Inc. | Glucose dehydrogenase polypeptides and related polynucleotides |
DK1722670T3 (da) | 2004-03-06 | 2014-01-06 | Hoffmann La Roche | Kropsfluidum-prøveudtagningsapparat |
US7172890B2 (en) * | 2004-10-28 | 2007-02-06 | Roche Diagnostics Gmbh | Inactivated enzyme variants and associated process and reagent system |
EP2093284A1 (de) * | 2008-02-19 | 2009-08-26 | F.Hoffmann-La Roche Ag | Stabilisierung von Dehydrogenasen mit stabilen Coenzymen |
WO2010009432A1 (en) | 2008-07-17 | 2010-01-21 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
EP2398909B1 (de) | 2009-02-19 | 2015-07-22 | F. Hoffmann-La Roche AG | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten |
-
2008
- 2008-02-19 EP EP08003054A patent/EP2093284A1/de not_active Ceased
-
2009
- 2009-02-18 TW TW098105120A patent/TWI482860B/zh active
- 2009-02-19 KR KR1020127027270A patent/KR20120134142A/ko not_active Application Discontinuation
- 2009-02-19 AU AU2009216908A patent/AU2009216908B9/en not_active Revoked
- 2009-02-19 KR KR1020107020894A patent/KR101381004B1/ko active IP Right Grant
- 2009-02-19 JP JP2010547110A patent/JP5758128B2/ja not_active Expired - Fee Related
- 2009-02-19 CN CN201410680334.8A patent/CN104450659A/zh active Pending
- 2009-02-19 EP EP09712033.1A patent/EP2245152B1/de active Active
- 2009-02-19 AR ARP090100571A patent/AR070436A1/es not_active Application Discontinuation
- 2009-02-19 WO PCT/EP2009/001206 patent/WO2009103540A1/de active Application Filing
- 2009-02-19 MX MX2010008920A patent/MX2010008920A/es active IP Right Grant
- 2009-02-19 RU RU2010138610/10A patent/RU2499834C2/ru not_active IP Right Cessation
- 2009-02-19 CN CN200980105640.6A patent/CN101945999B/zh not_active Expired - Fee Related
- 2009-02-19 CA CA2721718A patent/CA2721718C/en not_active Expired - Fee Related
- 2009-02-19 KR KR1020137013118A patent/KR20130081300A/ko not_active Application Discontinuation
- 2009-02-19 BR BRPI0907839-8A patent/BRPI0907839A2/pt not_active Application Discontinuation
-
2010
- 2010-02-12 JP JP2011550531A patent/JP6113405B2/ja not_active Expired - Fee Related
- 2010-02-12 CN CN2010800085457A patent/CN102325896A/zh active Pending
- 2010-08-19 US US12/859,654 patent/US9896666B2/en active Active
- 2010-09-16 ZA ZA2010/06638A patent/ZA201006638B/en unknown
-
2015
- 2015-09-23 HK HK15109305.4A patent/HK1208703A1/xx unknown
-
2018
- 2018-01-11 US US15/868,055 patent/US11220674B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033936A1 (en) * | 1997-02-04 | 1998-08-06 | Specialty Assays, Inc. | The use of nadph and nadh analogs in the measurement of enzyme activities and metabolites |
WO2001049247A2 (en) * | 1999-12-30 | 2001-07-12 | Specialty Assays, Inc. | Assays for analytes and enzymes practiced in the presence of nad and nadp analogues, and related assay kits |
US20070026476A1 (en) * | 2005-07-28 | 2007-02-01 | Dieter Heindl | Compounds, methods, complexes, apparatuses and uses relating to stabile forms of nad/nadh |
WO2007012494A1 (de) * | 2005-07-28 | 2007-02-01 | F.Hoffmann-La Roche Ag | Stabile nad/nadh-derivate |
Non-Patent Citations (2)
Title |
---|
LIAO MIN-HUNG ET AL: "Characteristics of magnetic nanoparticles-bound YADH in water/AOT/isooctane microemulsions", JOURNAL OF MOLECULAR CATALYSIS B ENZYMATIC, vol. 18, no. 1-3, 13 September 2002 (2002-09-13), pages 81 - 87, XP002502967, ISSN: 1381-1177 * |
SLAMA J T ET AL: "INHIBITION OF NAD GLYCOHYDROLASE AND ADP-RIBOSYLTRANSFERASES BY CARBOCYCLIC ANALOGUES OF OXIDIZED NAD", BIOCHEMISTRY, vol. 28, no. 19, 1989, pages 7688 - 7694, XP002502968, ISSN: 0006-2960 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11220674B2 (en) | 2008-02-19 | 2022-01-11 | Roche Diabetes Care, Inc. | Stabilization of dehydrogenases with stable coenzymes |
CN102325896A (zh) * | 2008-02-19 | 2012-01-18 | 霍夫曼-拉罗奇有限公司 | 干化学层中具有低活性的酶的快速反应动力学 |
US9896666B2 (en) | 2008-02-19 | 2018-02-20 | Roche Diabetes Care, Inc. | Stabilization of dehydrogenases with stable coenzymes |
WO2010094632A1 (de) * | 2009-02-19 | 2010-08-26 | F. Hoffmann-La Roche Ag | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten |
US9359634B2 (en) | 2009-02-19 | 2016-06-07 | Roche Diabetes Care, Inc. | Fast reaction kinetics of enzymes having low activity in dry chemistry layers |
US20130052674A1 (en) * | 2009-12-16 | 2013-02-28 | Carina Horn | Detecting the decomposition of enzymes in a test element by means of controlled release of a protected analyte |
JP2013524770A (ja) * | 2009-12-16 | 2013-06-20 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 保護された分析物の制御された放出によるテストエレメントにおける酵素の分解の検出 |
US10260085B2 (en) * | 2009-12-16 | 2019-04-16 | Roche Diabetes Care, Inc. | Detecting the decomposition of enzymes in a test element by means of controlled release of a protected analyte |
US9983140B2 (en) | 2012-06-22 | 2018-05-29 | Roche Diabetes Care, Inc. | Method and device for detecting an analyte in a body fluid |
US9255885B2 (en) | 2012-06-22 | 2016-02-09 | Roche Diabetes Care, Inc. | Method and device for detecting an analyte in a body fluid |
US10309905B2 (en) | 2012-06-22 | 2019-06-04 | Roche Diabetes Care, Inc. | Method and device for detecting an analyte in a body fluid |
WO2013189880A1 (en) | 2012-06-22 | 2013-12-27 | Roche Diagnostics Gmbh | Method and device for detecting an analyte in a body fluid |
WO2014096174A1 (en) | 2012-12-20 | 2014-06-26 | Roche Diagnostics Gmbh | Method for evaluating medical measurement curves |
US11060978B2 (en) | 2012-12-20 | 2021-07-13 | Roche Diabetes Care, Inc. | Methods of determining an analyte concentration in a body fluid sample having disturbance variables, as well as computer programs and devices therefor |
US10900957B2 (en) | 2013-03-19 | 2021-01-26 | Roche Diabetes Care, Inc. | Method and device for generating a corrected value of an analyte concentration in a sample of a body fluid |
EP2781919A1 (de) | 2013-03-19 | 2014-09-24 | Roche Diagniostics GmbH | Verfahren/Vorrichtung zur Erzeugung eines korrigierten Werts einer Analytenkonzentration in einer Körperflüssigkeitsprobe |
WO2014147074A1 (en) | 2013-03-19 | 2014-09-25 | Roche Diagnostics Gmbh | Method / device for generating a corrected value of an analyte concentration in a sample of a body fluid |
WO2014180939A1 (en) | 2013-05-08 | 2014-11-13 | Roche Diagnostics Gmbh | Stabilization of enzymes by nicotinic acid |
US11105800B2 (en) | 2013-10-29 | 2021-08-31 | Roche Diabetes Care, Inc. | Nano-enzyme containers for test elements |
US11029309B2 (en) | 2013-11-27 | 2021-06-08 | Roche Diabetes Care, Inc. | Composition comprising up-converting phosphors for detecting an analyte |
US10168321B2 (en) | 2013-11-27 | 2019-01-01 | Roche Diabetes Care, Inc. | Composition comprising up-converting phosphors for detecting an analyte |
EP2927319A1 (de) | 2014-03-31 | 2015-10-07 | Roche Diagnostics GmbH | Hochlastenzymimmobilisierung mittels Quervernetzung |
US10400233B2 (en) | 2014-03-31 | 2019-09-03 | Roche Diabetes Care, Inc. | High load enzyme immobilization by crosslinking |
US9988358B2 (en) | 2014-04-14 | 2018-06-05 | Roche Diagnostics Operations, Inc. | Phenazinium mediators |
EP3757096A1 (de) | 2014-08-22 | 2020-12-30 | Roche Diagnostics GmbH | Redoxindikatoren |
WO2016026959A1 (en) | 2014-08-22 | 2016-02-25 | Roche Diagnostics Gmbh | Redoxindicators |
WO2018067235A1 (en) | 2016-10-05 | 2018-04-12 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
US11230727B2 (en) | 2016-10-05 | 2022-01-25 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
WO2018115422A1 (en) | 2016-12-22 | 2018-06-28 | Roche Diabetes Care Gmbh | Glucose dehydrogenase variants with improved properties |
EP3339431A1 (de) | 2016-12-22 | 2018-06-27 | Roche Diabetes Care GmbH | Glucosedehydrogenasevarianten mit verbesserten eigenschaften |
WO2019166394A1 (en) | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | Biocompatibility coating for continuous analyte measurement |
US11925460B2 (en) | 2018-02-28 | 2024-03-12 | Roche Diabetes Care, Inc. | Biocompatibility coating for continuous analyte measurement |
US12024735B2 (en) | 2021-12-10 | 2024-07-02 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2245152B1 (de) | Stabilisierung von dehydrogenasen mit stabilen coenzymen | |
EP2467478B1 (de) | Stabilisierung von enzymen mit stabilen coenzymen | |
DE60223635T2 (de) | Reagenzien, Verfahren und Vorrichtungen zum Nachweis von Analyten | |
EP2779900B1 (de) | Analaysegerät zum nachweis mindestens eines analyten in einer probe | |
EP2510354B1 (de) | Sterilisierbare chemie für testelemente | |
EP2513648B1 (de) | Detektion der zersetzung von enzymen in einem testelement durch kontrollierte freisetzung von geschütztem analyt | |
WO2010094632A1 (de) | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten | |
EP2287605A1 (de) | Vereinfachte Magazinierung integrierter Systeme | |
EP2398909B1 (de) | Schnelle reaktionskinetik von enzymen mit niedriger aktivität in trockenen chemieschichten | |
WO2014128271A1 (de) | Hocheffiziente herstellung von blutglucose-teststreifen | |
EP0004639A2 (de) | Stabilisierte Nicotinamid-adenin-dinucleotide, Verfahren zu ihrer Herstellung und Verwendung eines Stabilisators | |
AU2012203453B2 (en) | Stabilization of dehydrogenases using stable coenzymes | |
DE602004002084T2 (de) | Methode und Reagenz zur quantitativen Bestimmung von Homocystein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980105640.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09712033 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/008920 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 587397 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010547110 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009216908 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009216908 Country of ref document: AU Date of ref document: 20090219 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009712033 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5773/CHENP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20107020894 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010138610 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2721718 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: PI0907839 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100819 |